Lau Laboratory

Alfred Gallegos

Education:

  • B.S. Microbiology University of Arizona, Tucson, AZ, 1986

Achievements:

  • Employee of the Year, College of Pharmacy 2005

Professional Experience:

  • Research Specialist Department of Pharmacology, University of Arizona 2008-2010
  • Research Specialist Sr. Arizona Cancer Center 1992-2002, 2006-2008
  • Research Specialist Sr. College of Pharmacy 2002-2006
  • Research Assistant II Department of Biochemistry, University of Arizona, 1982-1991
  • Lab Assistant/Phlebotomist Kino Community Hospital 1982-1983

Mentee:

Yurika Isoe, Itzel Rojas

Research Project:

Alfred is investigating mechanisms behind retinoid-induced cytoprotection of Ischemia Reperfusion Injury, with a focus on the involvement of antioxidant gene regulator Nrf2. Acute Kidney Injury (AKI) affects approximately five percent of all hospitalized patients.  One major cause of AKI is renal ischemia reperfusion injury (IRI).  IRI induces damage via initial hypoxia due to blockage of renal blood flow and the immune/oxidative response upon subsequent blood reperfusion.  Retinoids are a class of compounds related to vitamin A and have displayed roles in the cell progression and homeostasis of tissues. IRI is shown to be ameliorated with retinoid pretreatment in in vitro and in vivo models.

Publications:

  • Cohen J.D., Tham K.Y., Mastrandrea N.J., Gallegos A.C., Monks T.J., Lau S.S. cAMP-Dependent Cytosolic Mislocalization of p27kip-cyclin D1 During Quinol-Thioether Induced Tuberous Sclerosis Renal Cell Carcinoma. Toxicol Sci. 2011 Jun 20. [Epub ahead of print]
  • Baker A.F., Koh M.Y., Williams R.R., James B., Wang H., Tate W.R., Gallegos A., Von Hoff D.D., Han H., Powis G. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008 Mar;36(2):178-86.
  • Raffel J., Bhattacharyya A.K., Gallegos A., Cui H., Einspahr J.G., Alberts D.S., Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 2003 Jul;142(1):46-51.

  • Berggren M.I., Husbeck B., Samulitis B., Baker A.F., Gallegos A., Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys. 2001 Aug 1;392(1):103-9.

  • Engman L., Kandra T., Gallegos A., Williams R., Powis G. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des. 2000 Oct;15(5):323-30.

  • Hu Y., Qiao L., Wang S., Rong S.B., Meuillet E.J., Berggren M., Gallegos A., Powis G., Kozikowski A.P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem. 2000 Aug 10;43(16):3045-51.

  • Grogan T.M., Fenoglio-Prieser C., Zeheb R., Bellamy W., Frutiger Y., Vela E., Stemmerman G., Macdonald J., Richter L., Gallegos A., Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol. 2000 Apr;31(4):475-81.

  • Yeates L.C., Gallegos A., Kozikowski A.P., Powis G. Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth. Anticancer Res. 1999 Sep-Oct;19(5B):4171-6.

  • Freemerman A.J., Gallegos A., Powis G. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 1999 Aug 15;59(16):4090-4.

  • Qiao L., Nan F., Kunkel M., Gallegos A., Powis G., Kozikowski A.P.. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J Med Chem. 1998 Aug 27;41(18):3303-6.

  • Gallegos A., Berggren M., Gasdaska J.R., Powis G. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res. 1997 Nov 1;57(21):4965-70.

  • Berggren M., Gallegos A., Gasdaska J., Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res. 1997 Sep-Oct;17(5A):3377-80.

  • Dvorakova K., Dorr R.T., Gallegos A., McClure T., Powis G. Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. J Chromatogr B Biomed Sci Appl. 1997 Aug 29;696(2):275-81.

  • Powis G., Gallegos A., Abraham R.T., Ashendel C.L., Zalkow L.H., Dorr R., Dvorakova K., Salmon S., Harrison S., Worzalla J. Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. Cancer Chemother Pharmacol. 1997;41(1):22-8.

  • Gallegos A., Gasdaska J.R., Taylor C.W., Paine-Murrieta G.D., Goodman D., Gasdaska P.Y., Berggren M., Briehl M.M., Powis G. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res. 1996 Dec 15;56(24):5765-70.

  • Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 1996 Nov-Dec;16(6B):3459-66.

  • Gasdaska J.R., Gasdaska P.Y., Gallegos A., Powis G. Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. Genomics. 1996 Oct 15;37(2):257-9.

  • Powis G., Gasdaska P.Y., Gallegos A., Sherrill K., Goodman D. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res. 1995 Jul-Aug;15(4):1141-5.

  • Schultz R.M., Merriman R.L., Andis S.L., Bonjouklian R., Grindey G.B., Rutherford P.G., Gallegos A., Massey K., Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 1995 Jul-Aug;15(4):1135-9.

  • Frew T., Powis G., Berggren M., Gallegos A., Abraham R.T., Ashendel C.L., Zalkow L.H., Hudson C., Gruszecka-Kowalik E., Burgess E.M., et al. Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase. Anticancer Drug Des. 1995 Jun;10(4):347-59.

  • Powis G., Berggren M., Gallegos A., Frew T., Hill S., Kozikowski A., Bonjouklian R., Zalkow L., Abraham R., Ashendel C., et al. Advances with phospholipid signalling as a target for anticancer drug development. Acta Biochim Pol. 1995;42(4):395-403. Review.

  • Powis G., Bonjouklian R., Berggren M.M., Gallegos A., Abraham R., Ashendel C., Zalkow L., Matter W.F., Dodge J., Grindey G., et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994 May 1;54(9):2419-23.

  • Oblong J.E., Chantler E.L., Gallegos A., Kirkpatrick D.L., Chen T., Marshall N., Powis G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother Pharmacol. 1994;34(5):434-8.

  • Powis G., Gallegos A., Abraham R.T., Ashendel C.L., Zalkow L.H., Grindey G.B., Bonjouklian R. Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues. Cancer Chemother Pharmacol. 1994;34(4):344-50.

  • Brunn G., Fauq A.H., Chow S., Kozikowski A.P., Gallegos A., Powis G. Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity. Cancer Chemother Pharmacol. 1994;35(1):71-9.

  • Berggren M.I., Gallegos A., Dressler L.A., Modest E.J., Powis G. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res. 1993 Sep 15;53(18):4297-302.

  • Komm B.S., Terpening C.M., Benz D.J., Graeme K.A., Gallegos A., Korc M., Greene G.L., O'Malley B.W., Haussler M.R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988 Jul 1;241(4861):81-4.

  • Yamaoka K., Marion S.L., Gallegos A., Haussler M.R. 1,25-Dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochem Biophys Res Commun. 1986 Sep 30;139(3):1292-8.

Past and present staff

Present Graduate Students

Ryan Canatsey | Owen Kinsky | Chris Kuhlman | Nick Mastrandrea | Jessica Sapiro | Kevin Xu


Present Postdoctoral Fellow
Tim Radabaugh

Research Associate

Alfred Gallegos

Clinical Faculty Mentee

Hussein Yassine

Current Undergraduate Students

Wesley Cai, Itzel Rojas, Audrey Shi, Kim Tham


Recent Past Staff
Martina Bowen | Jennifer Cohen | Ashley Fisher | Chris Hattan | Mike Kimzey | Matt Labenski | Jean Lord-Garcia

 

 

 

 

The University of Arizona | Pharmacy Home Page | Pharmacology and Toxicology Home Page
Southwest Environmental Health Sciences Center | BIO5 | Arizona Cancer Center
Graduate Training in Toxicology and Toxicogenomics | Human Gene and the Environment Research
National Institute of Environmental Health Sciences